Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies ...

Mutations that cause spinal muscular atrophy (SMA) may lead to abnormalities in the development of cells in the spinal cord, a study found.

Biogen’s salanersen is now heading into three Phase III trials in SMA.

Insmed has launched a first-in-human Phase 1 trial testing its experimental ALS gene therapy INS1202 in people with the disease.

SMA newborn screening may help infants start treatment sooner, which researchers say could support better motor development outcomes.